Stockscreener 앱 받기
13.35
4.64%
-0.65
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7%Here's Why - MarketBeat
Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Singapore
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $28.34, Implies 88% Upside - TradingView
Summit Therapeutics (SMMT) Stock Gains on China Label Expansion for Ivonescimab - GuruFocus
Summit lead drug granted China label expansion (SMMT:NASDAQ) - Seeking Alpha
Can Summit Therapeutics (NASDAQ:SMMT) Extend Its Momentum? - Kalkine Media
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partners - MarketBeat
Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 - marketscreener.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Above 50-Day Moving AverageTime to Sell? - MarketBeat
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative? - Sahm
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics - GlobeNewswire
Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics - Oncodaily
Summit Therapeutics (SMMT) Launches Global Phase II/III Trial fo - GuruFocus
Summit TherapeuticsInitiates Global Phase Ii/Iii Harmoni-Gu1 Trial Of Ivonescimab In Bladder Cancer - TradingView
Summit Therapeutics (NASDAQ: SMMT) launches Phase II/III HARMONi-GU1 bladder cancer study - Stock Titan
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer - Business Wire
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates - Sahm
Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec'Carvana (NYSE:CVNA) - benzinga.com
The Manufacturers Life Insurance Company Has $11.24 Million Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Clear Street Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 117.69% Upside - DirectorsTalk Interviews
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches (SMMT) - Seeking Alpha
Summit Therapeutics (SMMT) Is Down 13.2% After Equity Offering And Ivonescimab Updates Has The Bull Case Changed? - Sahm
Summit Therapeutics Reports Q2 2026 Financial Results and Major Clinical Progress for Ivonescimab - Oncodaily
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
SMMT|Summit Therapeutics Inc|Price:13.105|Chg%:-0.555 - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Cash Flow - TradingKey
Summit Therapeutics officers investigated for p... - Pluang
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a 105.67% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations - The Globe and Mail
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Establishes $380 Million ATM Equity Program - The Globe and Mail
Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept - marketscreener.com
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
0.52%
0.07%
자본화:
|
볼륨(24시간):